Paul Dato, MD
Urology · la Mesa, CANPI 1588632715
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $293,979 of the $455,243 with a category attached, or 64.6%. 44 manufacturers reported payments, led by Johnson & Johnson at 26.7% of the total. 2025 is the largest year on record at $142,809, 4.2 times the $33,900 reported in 2019. Among urology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,360 payments — averaging $334.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$122K
- Bayer$92K
- Dendreon Pharmaceuticals LLC$69K
- Astellas Pharma US Inc$55K
- Sun Pharmaceutical Industries Inc.$33K
- Pfizer$26K
- plus $59K from 38 others
Across 52 payments — averaging $11,039 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Veru Inc.$209K
- Ortho-clinical Diagnostics, Inc.$192K
- Dendreon Pharmaceuticals LLC$140K
- Sumitomo Pharma America, Inc.$20K
- Epizyme, Inc.$11K
- Bayer$2K
What the payments were for
- Consulting fees$76,82517%
- Speaking & faculty fees$293,97965%
- Travel & lodging$46,18710%
- Food & beverage$37,4978%
- Education$7540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Erleada$94,628
- Nubeqa$76,979
- PROVENGE$64,281
- XTANDI$60,813
- AKEEGA$31,652
- YONSA$31,514
- ORGOVYX$26,727
- Xofigo$25,772
- RYBREVANT$23,167
- CARVYKTI$23,167
- ILLUCCIX$15,350
- FOCAL ONE$10,500
- TALZENNA$7,321
- Non-Covered$5,715
- ADSTILADRIN$2,684
- MOBILE LASER UNIT$900
- JELMYTO$384
- BRACAnalysis CDx$350
- Lupron Depot$325
- LYNPARZA$238
How this compares
$455,243 in reported general payments places this provider in the 95th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 242 | $3,040,463 |
| ErleadaApalutamide | 130 | $1,856,188 |
| OrgovyxRelugolix | 444 | $1,145,923 |
| NubeqaDarolutamide | 80 | $1,034,889 |
| Abiraterone Acetate | 195 | $327,505 |
| YonsaAbiraterone Acet,submicronized | 23 | $290,923 |
| Lupron DepotLeuprolide Acetate | 17 | $103,856 |
| EligardLeuprolide Acetate | 26 | $23,828 |
| MyrbetriqMirabegron | 28 | $20,276 |
| FirmagonDegarelix Acetate | 14 | $8,881 |
| Tamsulosin Hcl | 112 | $2,076 |
| Testosterone | 12 | $1,128 |
| Prednisone | 203 | $1,025 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 32 | $704 |
| Potassium Chloride | 15 | $557 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $54,807 | $3,060,738270 claims |
| Johnson & JohnsonErleada | $121,773 | $1,856,188130 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $941 | $1,145,923444 claims |
| BayerNubeqa | $91,637 | $1,034,88980 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $249 | $327,505195 claims |
| AbbVieLupron Depot | $1,087 | $103,85617 claims |
| Tolmar Pharmaceuticals, Inc.Eligard | $196 | $23,82826 claims |
| Ferring Pharmaceuticals Inc.Firmagon | $3,063 | $8,88114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,324 urology providers in California.
Other urology in la Mesa
- Franklin Gaylisla Mesa$81K
- Stephen FreedlandWest Hollywood$1.9M
- Arie BelldegrunLos Angeles$1.8M
- Mihir DesaiLos Angeles$1.5M
- Steven WilsonIndio$1.1M
- Stuart HoldenLos Angeles$1.1M
- Elward CrawfordSan Diego$849K
- Edward UchioOrange$849K
- Victor ChingUpland$809K
- Jaime LandmanOrange$657K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.